Investing.com - यूनाइटेड किंगडम ने Wockhardt Ltd WCKH.NS के साथ COVID-19 वैक्सीन की आपूर्ति के लिए छह महीने के लिए एक सौदा बढ़ाया है, भारतीय दवा निर्माता ने बुधवार को कहा।कंपनी...
प्रकार | 5 मिनट | 15 मिनट | प्रति घंटा | दैनिक | मासिक |
|---|---|---|---|---|---|
| मूविंग एवरेज | बेचना | बेचना | बेचना | मजबूत विक्रय | मजबूत विक्रय |
| तकनीकी संकेतक | मजबूत खरीद | बेचना | मजबूत विक्रय | मजबूत विक्रय | तटस्थ |
| सारांश | तटस्थ | बेचना | मजबूत विक्रय | मजबूत विक्रय | बेचना |
नाम | अंतिम | उच्च | निम्न | बदलाव | बदलाव % | वॉल्यूम | समय | ||
|---|---|---|---|---|---|---|---|---|---|
| 29.20 | 29.20 | 29.20 | -1.50 | -4.89% | 79.33K | BSE | |||
| 175.90 | 184.30 | 175.30 | -6.50 | -3.56% | 13.59M | NSE | |||
| 4.56 | 4.56 | 4.56 | +0.21 | +4.83% | 300.00 | BSE | |||
| 447.25 | 453.00 | 442.50 | -3.80 | -0.84% | 3.91M | NSE | |||
| 376.10 | 381.70 | 372.00 | -3.80 | -1.00% | 5.25M | NSE | |||
| 88.35 | 90.00 | 87.15 | -0.100 | -0.11% | 10.07K | NSE | |||
| 252.90 | 263.90 | 252.00 | -6.15 | -2.37% | 89.49K | NSE | |||
| 40.55 | 40.55 | 39.75 | +1.90 | +4.92% | 39.58M | NSE | |||
| 1,546.00 | 1,594.80 | 1,515.00 | -31.15 | -1.98% | 130.13K | NSE | |||
| 1,344.20 | 1,375.00 | 1,338.00 | -12.80 | -0.94% | 149.16K | NSE | |||
| 426.95 | 434.00 | 400.05 | +12.10 | +2.92% | 21.49K | BSE | |||
| 9.97 | 10.40 | 8.61 | +1.10 | +12.40% | 70.08K | BSE | |||
| 1,011.10 | 1,025.00 | 979.10 | +23.95 | +2.43% | 21.38K | NSE | |||
| 3,687.00 | 3,760.00 | 3,650.00 | -27.35 | -0.74% | 192.02K | NSE | |||
| 490.00 | 514.05 | 468.25 | +25.40 | +5.47% | 3.09M | NSE |
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, Europe, and internationally. The company offers generic products comprising injectables, such as cephalosporins and non-cephalosporins; molecules; and value-added generics. Its biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. The company also provides contract manufacturing services for sterile injectables, lyophilisation, and other dosage forms; and research services. It develops various molecules primarily in the area of infectious disease, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company was incorporated in 1999 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.